Market Closed -
Nasdaq Stockholm
11:13:08 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
40.45
SEK
|
+0.50%
|
|
+2.53%
|
+1.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,394
|
3,665
|
1,326
|
1,293
|
1,250
|
1,264
|
-
|
-
|
Enterprise Value (EV)
1 |
1,184
|
3,665
|
1,057
|
1,175
|
1,121
|
644.3
|
1,264
|
1,264
|
P/E ratio
|
-27.6
x
|
-63.6
x
|
-12.7
x
|
-9.12
x
|
-5.92
x
|
1.89
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
2.47%
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
9.65
x
|
1.6
x
|
0.79
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
4.92
x
|
1.6
x
|
0.79
x
|
EV / EBITDA
|
-28.3
x
|
-
|
-11.9
x
|
-9.51
x
|
-6.49
x
|
-2.32
x
|
5.43
x
|
1.28
x
|
EV / FCF
|
-9.38
x
|
-
|
-20
x
|
-
|
-5.44
x
|
-1.69
x
|
14
x
|
-
|
FCF Yield
|
-10.7%
|
-
|
-5.01%
|
-
|
-18.4%
|
-59.3%
|
7.12%
|
-
|
Price to Book
|
-
|
-
|
2.24
x
|
2.33
x
|
1.53
x
|
0.67
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,752
|
18,893
|
20,680
|
22,680
|
31,254
|
31,254
|
-
|
-
|
Reference price
2 |
83.20
|
194.0
|
64.10
|
57.00
|
40.00
|
40.45
|
40.45
|
40.45
|
Announcement Date
|
2/28/20
|
2/25/21
|
2/18/22
|
2/15/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
131
|
789
|
1,605
|
EBITDA
1 |
-41.76
|
-
|
-89.08
|
-123.5
|
-172.5
|
-278
|
233
|
986
|
EBIT
1 |
-46.56
|
-
|
-97.95
|
-133.1
|
-181.7
|
-293
|
214
|
946
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-223.66%
|
27.12%
|
58.94%
|
Earnings before Tax (EBT)
1 |
-45.77
|
-
|
-96.7
|
-131.7
|
-179.7
|
754.4
|
-
|
-
|
Net income
1 |
-45.77
|
-52.41
|
-96.7
|
-131.7
|
-179.7
|
596
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
454.97%
|
-
|
-
|
EPS
2 |
-3.010
|
-3.050
|
-5.030
|
-6.250
|
-6.760
|
21.42
|
-
|
-
|
Free Cash Flow
1 |
-126.2
|
-
|
-52.92
|
-
|
-206
|
-382
|
90
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-291.6%
|
11.41%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
38.63%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
1.000
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/25/21
|
2/18/22
|
2/15/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-49.98
|
-16.96
|
-26.82
|
-26.6
|
-53.16
|
EBIT
1 |
-52.28
|
-19.28
|
-29.21
|
-28.99
|
-55.59
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-51.94
|
-18.93
|
-28.86
|
-28.65
|
-55.22
|
Net income
1 |
-51.94
|
-18.93
|
-28.86
|
-28.65
|
-55.22
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.620
|
-0.9200
|
-1.400
|
-1.390
|
-2.480
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/18/22
|
5/6/22
|
8/5/22
|
11/9/22
|
2/15/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
210
|
-
|
269
|
118
|
129
|
620
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-126
|
-
|
-52.9
|
-
|
-206
|
-382
|
90
|
-
|
ROE (net income / shareholders' equity)
|
-13.5%
|
-
|
-
|
-
|
-
|
55%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
28.60
|
24.50
|
26.10
|
60.40
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
23.1
|
-
|
1.31
|
-
|
2.69
|
26
|
28
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
19.85%
|
3.55%
|
-
|
Announcement Date
|
2/28/20
|
2/25/21
|
2/18/22
|
2/15/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
40.45
SEK Average target price
107
SEK Spread / Average Target +164.52% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.12% | 115M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|